Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.43 |
| ▸ | GHSR | Q92847 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL443381 | 0.90 | TRPV1 (0.44) | KMT2AMEN1TRPV1GHSRMMP2 | |
| SCHEMBL2370528 | 0.83 | TRPV1 (0.46) | KMT2AMEN1TRPV1MAPTMMP2 | |
| SCHEMBL1016475 | 0.80 | SMN1; SMN2 (0.45) | KMT2AMEN1TRPV1MAPTALDH1A1 | |
| SCHEMBL3348070 | 0.79 | KIF11 (0.45) | KMT2AMEN1TRPV1MAPTALDH1A1 | |
| SCHEMBL2369624 | 0.79 | EPHX1 (0.50) | EPHX1ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4050500 | 0.78 | KMT2A (0.60) | KMT2AMEN1TRPV1MAPTEPHX1 | |
| SCHEMBL1832517 | 0.77 | EPHX1 (0.57) | KMT2AMEN1EPHX1ALDH1A1NPC1 | |
| SCHEMBL1991350 | 0.76 | CYP17A1 (0.43) | TRPV1NAMPT | |
| SCHEMBL6610808 | 0.73 | CYP17A1 (0.49) | NAMPT | |
| SCHEMBL3519257 | 0.73 | TRPV1 (0.32) | TRPV1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249129-B2 | Morpholino substituted urea derivatives as mTOR inhibitors | CELLZOME LIMITED (GB) | 2016-02-02 | — | — | US | disclosed |
| EP-2542536-B1 | Morpholino substituted urea derivatives as mtor inhibitors | CELLZOME LTD (GB) | 2015-01-21 | — | — | EP | disclosed |
| US-20130196982-A1 | MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2013-08-01 | — | — | US | disclosed |
| EP-2542536-A1 | MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS | Cellzome Limited (GB) | 2013-01-09 | — | — | EP | disclosed |
| WO-2011107585-A1 | MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196982-A1 | MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS | MTOR, EIF4E, EIF4A1 | KMT2A 1849/4885MEN1 572/4885TRPV1 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.